The explosion Medicare Advantage special needs plan enrollment reached 21% in 2025, driven by targeted care for chronic and ...
CMS accepting comments on data collection requirements for Medicare Advantage plans, Part D sponsors
The Centers for Medicare & Medicaid Services is seeking comments by May 11 on its proposed revisions to data reporting requirements for Medicare Advantage and Part D plans, according to a Paperwork ...
New disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis are usually expensive and insurers, including ...
GLP-1 medications, such as Ozempic, Zepbound and Wegovy, have emerged as a significant advancement in the treatment of various conditions, including Type 2 diabetes, heart ...
Eli Lilly says some Medicare Part D plans may not follow the $50 monthly cap for weight‑loss drugs under a new CMS coverage ...
Medicare Advantage beneficiaries face forced disenrollment in 2026 as plan exits drive coverage termination, pushing millions toward traditional Medicare and Part D’s $2100 cap. The era of predictable ...
Current Medicare Advantage enrollees have until March 31 to switch plans, either to another private Medicare Advantage plan or a government Medicare original coverage. Here's what experts say ...
Dear Toni: I delayed enrolling in Medicare Part B because I was working with employer benefits. I recently turned 70 and retired Jan. 1. I have enrolled in a Medicare supplement Plan G and Part D ...
I delayed enrolling in Medicare Part B because I was working with employer benefits. Recently I turned 70 and am retiring effective Jan. 1. I have enrolled in a Medicare Supplement Plan G and Part D ...
McDermott+ is pleased to bring you Regs & Eggs, a weekly Regulatory Affairs blog by Jeffrey Davis. January 29, 2026 – Earlier this week, the Centers for Medicare & Medicaid Services (CMS) released the ...
Medicare enrollees can expect new rules and benefits in 2026. Even if you have original Medicare, which tends to have stability in hospital and medical coverage, you should be aware of changes to ...
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results Early-year entry into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results